Giuseppe Viale

Research interests

Publications

• Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-03261-7

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab -Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2021 · https://doi.org/10.1093/jnci/djab108

• Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.01204

• Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

  Cancer Cell · 2021 · https://doi.org/10.1016/j.ccell.2021.03.004

• Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2105215

• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.02309

• HER2-Low Breast Cancer: Pathological and Clinical Landscape

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02488

• Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30812-x

• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.77.8738

• Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30380-2

• Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30261-4

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30777-5

• Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1703643

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · 10.1093/annonc/mdx308

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000162

• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1602253

• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  Modern Pathology · 2015 · https://doi.org/10.1038/modpathol.2015.98

• A gut-vascular barrier controls the systemic dissemination of bacteria

  Science · 2015 · https://doi.org/10.1126/science.aad0135

• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu450

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70035-4

• Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.50.9984

• Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2011.41.0902

• Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.3769

• Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model

  Gut · 2012 · https://doi.org/10.1136/gutjnl-2011-300971

• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds586

• Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content

  Cell · 2010 · 10.1016/j.cell.2009.12.007

• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.6529

• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)

  Archives of Pathology & Laboratory Medicine · 2010 · 10.5858/134.7.e48

• Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells

  Gut · 2009 · https://doi.org/10.1136/gut.2008.175166

• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2765

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

• Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj415

• Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells

  Nature Immunology · 2005 · https://doi.org/10.1038/ni1192

• A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer

  New England Journal of Medicine · 2003 · 10.1056/nejmoa012782

• A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers

  JNCI Journal of the National Cancer Institute · 2003 · https://doi.org/10.1093/jnci/95.11.779

• Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes

  The Lancet · 1997 · 10.1016/s0140-6736(97)01004-0

Current projects

No projects listed.